Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + azacitidine + donor lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
camrelizumab + azacitidine + donor lymphocyte infusion is a combination therapeutic regimen being investigated by The First Affiliated Hospital of Soochow University for the treatment of relapsed Acute Myeloid Leukemia (AML) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The regimen combines camrelizumab, a monoclonal antibody targeting the Programmed cell death protein 1 (PD-1) checkpoint, with azacitidine, a hypomethylating agent, and low-dose donor lymphocyte infusion (DLI). Azacitidine is utilized to upregulate the expression of tumor-associated antigens and HLA molecules, potentially enhancing the immunogenicity of leukemic cells. Camrelizumab is intended to reverse T-cell exhaustion and reinvigorate the anti-tumor activity of the infused donor lymphocytes. This synergistic approach aims to maximize the graft-versus-leukemia (GVL) effect to induce remission in patients with post-transplant relapse while carefully managing the risk of graft-versus-host disease (GVHD).
- Other names
- PD-1 inhibitor + Azacitidine + low-dose DLICamrelizumab + Azacitidine + DLI
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on camrelizumab + azacitidine + donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + azacitidine + donor lymphocyte infusion.